Wednesday, March 09, 2022 2:48:16 PM
I disagree Maverick0408, if Linda Powers and the rest of the NWBio management team, can continue to execute on the following:
(1) successfully navigate through all the challenges and obstacles inherent in completing a multi-national Phase III clinical trial, in 4 different countries (US, UK, Canada, Germany) for 1 of the most difficult to treat diseases in the world, and where dozens of other large & small pharmaceutical companies, who have tried since 2005 have failed;
(2) overcome the torrrent of resistance from legal and illegal shorts, hedge funds, and other who have been actively and aggressively trying to stop NWBio from succeeding;
(3) overcome the barrage of coordinated and concerted disinformation, misinformation and outright lies about NWBio and the DCVax vaccine platform, all across social media, message boards, chat roooms, etc;
(4) finally, release positive DCVax-L TLD and journal article; and
(5) Obtain regulatory approvals for DCVax-L in the US, UK, Canada, Germany and the rest of the EU.
Others may hop off this train after TLD and a nice pop in NWBO share price. There is nothing wrong with that, and that is totally their decision.
I will continue to ride with this management team beyond this first phase of success (regulatory approval in the US, UK, Canada, Germany and the rest of the EU), until the facts on the ground tells me that they have stopped executing their additional business plans (DCVax Direct positive trials & approvals, DCVax-L approvals for other solid tumor cancers, etc.
(1) successfully navigate through all the challenges and obstacles inherent in completing a multi-national Phase III clinical trial, in 4 different countries (US, UK, Canada, Germany) for 1 of the most difficult to treat diseases in the world, and where dozens of other large & small pharmaceutical companies, who have tried since 2005 have failed;
(2) overcome the torrrent of resistance from legal and illegal shorts, hedge funds, and other who have been actively and aggressively trying to stop NWBio from succeeding;
(3) overcome the barrage of coordinated and concerted disinformation, misinformation and outright lies about NWBio and the DCVax vaccine platform, all across social media, message boards, chat roooms, etc;
(4) finally, release positive DCVax-L TLD and journal article; and
(5) Obtain regulatory approvals for DCVax-L in the US, UK, Canada, Germany and the rest of the EU.
Others may hop off this train after TLD and a nice pop in NWBO share price. There is nothing wrong with that, and that is totally their decision.
I will continue to ride with this management team beyond this first phase of success (regulatory approval in the US, UK, Canada, Germany and the rest of the EU), until the facts on the ground tells me that they have stopped executing their additional business plans (DCVax Direct positive trials & approvals, DCVax-L approvals for other solid tumor cancers, etc.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
